Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

p38 kinase inhibitor RWJ-68354: a promising clinical candidate for inflammatory conditions

Nov. 19, 1998

Novel antibody with potential in treating RA investigated by Santen

Nov. 18, 1998

MMP inhibitor BMS-453 improves disease symptoms in mice with experimental arthritis

Nov. 18, 1998

SB pursues CCR5 antagonists for the treatment of inflammation

Nov. 18, 1998

New osteoarthritis treatment candidate blocks cartilage degradation

Nov. 18, 1998

MK-966 improves physical ability and quality of life in patients with OA, RA

Nov. 18, 1998

Amgen evaluates novel TNF-targeted immunotherapy in patients with active RA

Nov. 17, 1998

Stromelysin inhibitor Bay-12-9566 enters clinical testing for a second indication

Nov. 17, 1998

TheraTech achieves targeted delivery of doxorubicin to inflammatory sites in mice with CIA

Nov. 16, 1998

Celecoxib studies continue to generate impressive efficacy and safety data

Nov. 16, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...